How does gemfibrozil affect exposure to the pioglitazone component of Competact?

Gemfibrozil, a CYP2C8 inhibitor, reportedly increases exposure (AUC) to pioglitazone, a component of Competact, threefold; a pioglitazone dose reduction may be needed because dose-related adverse effects may increase, and close monitoring of glycaemic control should be considered.